This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of Escitalopram for Depression in Patients With Diabetes (EFDID)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: March 30, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
Patients with diabetes and major depression treated with Escitalopram might experience significant improvement in depression and anxiety scores; functional ability; diabetes-related self-care; and pain symptoms

Condition Intervention Phase
Major Depression Diabetes Mellitus Drug: Escitalopram Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • Depressive symptoms [ Time Frame: 14 weeks ]

Secondary Outcome Measures:
  • Diabetes self-care [ Time Frame: 14 weeks ]

Estimated Enrollment: 30
Study Start Date: April 2008
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Patients with Diabetes Mellitus and Major Depression
Drug: Escitalopram
10-20 mg once daily

Detailed Description:
Major depression is common in patients diabetes (point prevalence about 15-20%). It has been shown that patients with diabetic and major depression experience more severe diabetes symptoms, greater disability, more frequent medical complications, greater healthcare utilization costs, poorer glycemic control, and greater difficulties with diabetes self-care activities, compared with patients with diabetes without depression. Few specific features of Escitalopram, a selective serotonin reuptake inhibitor (SSRI), make it a promising medication for use in diabetes. These include a benign side effect profile; high tolerance in elderly patients; rapid action with efficacy often demonstrated in as little 1-2 weeks, which in turn could help improve compliance; its efficacy for treatment of generalized anxiety disorder, which may also be relatively common in patients with diabetes, and co-occurs frequently with depression. This study is designed to test the efficacy of Escitalopram for the treatment of major depression in patients with diabetes mellitus.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older.
  • Diagnosis of Type-1 or Type-2 diabetes mellitus (excluding gestational diabetes) by a specialist at least 6 months prior to the study.
  • Current diagnosis of major depression based on DSM-IV criteria .
  • Hamilton Depression Rating Scale (HAMD) baseline score > 17
  • Available for 14-weeks of treatment and all evaluations.
  • Able to understand study rules and procedures and willing to sign written informed consent for study participation.

Exclusion Criteria:

  • Competence: Not competent to understand and sign informed consent forms and/or to understand and answer the evaluations.
  • Psychiatric exclusions: One or more of the following: Alcohol or substance abuse or dependence in past 6 months; psychotic symptoms or history of psychosis; bipolar disorder; organic brain syndrome; significant suicide risk; homicidal thoughts.
  • Medical exclusions: Known intolerance or hypersensitivity to escitalopram or other SSRI; pregnancy; breastfeeding; women of childbearing potential not using adequate contraception; significant renal or hepatic dysfunction (such that demands medical workup and/or regular follow up); resting heart rate less than 40/minute (or 50/minute if symptomatic); uncontrolled hypertension (systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg); any acute or unstable medical condition that might interfere with the safe conduct of the study.
  • Concomitant medication(s) exclusion: Current use (within 2 weeks of enrollment) of one or more of the following: antidepressants; regular benzodiazepine; neuroleptics; anticonvulsants; reserpine; guanethidine; clonidine; methyldopa.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00650897

Contact: Raz Gross, MD; MPH 972-3-5303962
Contact: Galit Geulayov, MSc 972-3-5305180

Sheba Medical Center Not yet recruiting
Tel Hashomer, Israel
Principal Investigator: Raz Gross, MD; MPH         
Sub-Investigator: Ohad Cohen, MD         
Sub-Investigator: Galit Geulayov, MSc         
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Raz Gross, MD; MPH The Gertner Institute
  More Information

Responsible Party: Dr. Raz Gross, The Gertner Institute for Epidemiology and Health Policy Research Research Identifier: NCT00650897     History of Changes
Other Study ID Numbers: SHEBA-06-4426-RG-CTIL
Study First Received: March 30, 2008
Last Updated: March 30, 2008

Keywords provided by Sheba Medical Center:
Major Depression
Diabetes Mellitus
Self Care

Additional relevant MeSH terms:
Diabetes Mellitus
Depressive Disorder
Depressive Disorder, Major
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on August 16, 2017